*All times listed are Central European Time (CET)
7:20 am Morning Check-in, Coffee & Light Breakfast
8:20 am Chair’s Opening Remarks
Shaping Healthcare Policy & Regulations & Engaging Hospitals to Expand Access Across More Patients in Need
8:30 am Transforming the Lives of Patients Through Precision Radiopharmaceuticals: Patient & Health Care System Stories
Synopsis
- Learn about the positive impact radiopharmaceuticals are having on patient communities
- Hear from clinicians who have seen radiopharmaceuticals on boarded in hospitals and breaking down misconceptions
- Garner key insights to transform your clinical design and improve patient engagement
9:00 am Panel Discussion: Obstacles & Opportunities in the Pricing & Reimbursement of Radiopharmaceuticals Across European Countries – Comparing UK, France & Germany
Synopsis
- Influencing key decision makers within hospitals and how these feeds into healthcare policy making and, ultimately, further patient access
- Sharing experiences of industry-hospital collaborations
- Making legislation, regulation and policy making and how this came about in Europe
9:30 am Outlining the EANM Guidance Document: Dosimetry for First-in-human Studies & Early Phase Clinical Trials
Synopsis
- Exploring different emitters and carrier molecules
- Outlining methods for activity measurement, pharmacokinetic analyses, as well as absorbed dose calculations and uncertainty analyses
- Discussing the optimal use of preclinical information and studies involving diagnostic analogues
10:00 am Speed Networking & Refreshments
Preclinical & Translational Track
Finetuning Dosing & Toxicity Considerations for Radiopharmaceuticals to Ensure Patient Safety
11:00 am Optimising Dosing in Translational Radiopharmaceutical Studies
Synopsis
- Using dosimetry to help determine dosing
- Optimising treatment regimens
- Preclinical screening and computational modelling
11:30 am Affilin Molecules as a New Modality for Radiotheranostics
Synopsis
- Outlining scaffold-based ligands to provide an alternative to peptides and antibodies
- Molecular engineering allows modulation of in-vivo PK and BioD
11:45 am Fully Integrated Services for Radiopharmaceutical Development: From Lead Optimization to First-in-human Studies
Synopsis
- Sharing state-of-the-art facility for CRO and CDMO services
- Seamless transition from preclinical research to clinical trials
- Outlining advanced models within oncology, cardiovascular diseases and in vivo molecular imaging
12:00 pm Exploring Affibody Molecules as Vehicles for Molecular Radiotherapy of HER2- expressing Malignancies: ABY-025 for Patient Selection & ABY-271 for Radioligand Therapy
Synopsis
- Selecting patients by immunohistochemistry has limitations and image-guided decisions have recently proven superior
- Using the PET tracer ABY-025 todemonstrated correlation with improved treatment response prediction and can be translated therapeutically using linker technology for improved kinetics
- ABY-271 is a candidate in late preclinical development for molecular radiotherapy of HER2 expressing cancers
Clinical & Supply Chain Track
Strengthening Your Radiopharmaceutical Production & Transport Expertise to Ensure no Trial Hold Up
11:00 am Streamlining Your Radiopharmaceuticals Logistics Chains to Deliver Quality Drug Product to Patients on Time
Synopsis
- Exploring drug product release and quality assurance
- Optimising transport, tracking and delivery to ensure your drug doesn’t get hold up
- Uncovering tracking methods to streamline with patient
11:30 am Bringing Your Radiopharmaceutical to the Market – Your Expert Partner in Clinical Trials
Synopsis
- Supporting complex and pivotal studies
- Providing operational expertise
- PSI radiopharmaceutical training program
Presntation by PSI
11:45 am Secured Global Supply: Isotopia’s Three-Site Strategy for Advancing Lutetium-177 & Terbium-161 Across All Phases of Development to Serve the Patient
Synopsis
- Building a Global Strategy to Serve the Patient
- Next-Generation Isotope Solutions
12:00 pm Panel Discussion: A Supply Chain Lens: Exploring Isotope Viability from Production Challenges to Market Potential
Synopsis
- Assessing various isotopes and their supply challenges from continuing lutetium supply to
- actinium and lead
- Market potential and competition across isotope development
- Solutions for newer companies in the field
12:30 pm Lunch Break & Networking
1:00 pm
Preclinical & Translational Track
Supercharging the Field by Exploring Novel Radiopharmaceutical Targets
1:30 pm Radionuclide Therapy Improvement Using Radiosensitizers: Preclinical Studies & Future Outlook
Synopsis
- Showcasing various preclinical studies (in vitro and in vivo)
- Addressing different combination treatments of 177Lu-based radionuclide therapies and agents such as DNA damage repair inhibitors
Clinical & Supply Chain Track
Expanding Combination Based Approaches to Maximise Clinical Efficacy of TRPs
1:30 pm Bringing Novel Targets to the Clinic
Synopsis
- Novel target selection to expand use in different solid tumors
- Vector selection: Small molecules or mAb or both?
- Sharing topline clinical imaging data
2:00 pm Afternoon Break & Networking
Amplifying the Field: Spanning More Targets & Advancing Indications with Radiopharmaceuticals
2:30 pm Uncovering Novel Radiopharmaceutical Targets DLL3
Synopsis
- Uncovering targeting potential
- Preclinical insights
- Treatment potential for tough to treat lung cancer
3:00 pm Assessing Future Directions for Addressing Unmet Medical Need by Expanding Indications & Selecting Novel Targets
Synopsis
- Identifying existing targets to be adapted to radiopharmaceuticals
- Exploring areas of unmet need and market potential
- Uncovering market predictions
3:30 pm Illuminating Advances in Click – Cleavable Radioimmunotherapy Programme
Synopsis
- Increasing efficacy and decreasing toxicity with click chemistry
- Ensuring off-target deactivation of unwanted circulating radiopharmaceuticals
4:00 pm Chair’s Closing Remarks
4:10 pm End of Conference
